Add-on of aripiprazole improves outcome in clozapine-resistant schizophrenia

Alessandro De Risio, Angelo Pancheri, Giovanna Simonetti, Diana Giannarelli, Luciana Stefanutto, Bruno Gentile

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Although clozapine proved effective in treating 30-50% of the cases of resistant schizophrenia, its clinical use is hampered by significant side effects. To overcome this problem, augmentation with other atypical antipsychotics has been attempted, with conflicting results. A clozapine-aripiprazole combination showed interesting properties, due to the favourable complementary pharmacodynamic receptor profile and to the negligible metabolic interactions. In this retrospective case series, we investigated the change in BPRS scores and metabolic features like BMI, fasting glucose, total and LDL cholesterol, triglycerides, functional outcome HoNOS Rome and PSP scores after aripiprazole augmentation in 16 persons with treatment-resistant schizophrenia who were already treated with clozapine. The results demonstrated a statistically significant improvement in metabolic indices, psychopathology and functional outcome measures from baseline to endpoint (6. weeks) after augmentation with aripiprazole. Statistically significant correlations were observed between psychopathological and behavioural measures at baseline and at endpoint. Linear regression analysis defined a tripartite model, in which item HoNOS Rome 11, measuring autonomy in everyday life, explained nearly half of functional outcome PSP score predictive variance, together with BPRS total psychopathology score and HoNOS Rome total social functioning score. Adequately conducted randomised double-blind studies should provide further specific data highlighting the role of a clozapine-aripiprazole combination in improving functional outcome of persons with treatment-resistant schizophrenia.

Original languageEnglish
Pages (from-to)1112-1116
Number of pages5
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume35
Issue number4
DOIs
Publication statusPublished - Jun 1 2011

Fingerprint

Clozapine
Schizophrenia
Psychopathology
Double-Blind Method
LDL Cholesterol
Antipsychotic Agents
Linear Models
Fasting
Regression Analysis
Outcome Assessment (Health Care)
Glucose
Aripiprazole
Primary Spontaneous Pneumothorax

Keywords

  • Aripiprazole
  • Clozapine
  • Retrospective case series
  • Schizophrenia

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Cite this

Add-on of aripiprazole improves outcome in clozapine-resistant schizophrenia. / De Risio, Alessandro; Pancheri, Angelo; Simonetti, Giovanna; Giannarelli, Diana; Stefanutto, Luciana; Gentile, Bruno.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 35, No. 4, 01.06.2011, p. 1112-1116.

Research output: Contribution to journalArticle

De Risio, Alessandro ; Pancheri, Angelo ; Simonetti, Giovanna ; Giannarelli, Diana ; Stefanutto, Luciana ; Gentile, Bruno. / Add-on of aripiprazole improves outcome in clozapine-resistant schizophrenia. In: Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2011 ; Vol. 35, No. 4. pp. 1112-1116.
@article{d7844416a4f24d5b9cb9ae54763f64c4,
title = "Add-on of aripiprazole improves outcome in clozapine-resistant schizophrenia",
abstract = "Although clozapine proved effective in treating 30-50{\%} of the cases of resistant schizophrenia, its clinical use is hampered by significant side effects. To overcome this problem, augmentation with other atypical antipsychotics has been attempted, with conflicting results. A clozapine-aripiprazole combination showed interesting properties, due to the favourable complementary pharmacodynamic receptor profile and to the negligible metabolic interactions. In this retrospective case series, we investigated the change in BPRS scores and metabolic features like BMI, fasting glucose, total and LDL cholesterol, triglycerides, functional outcome HoNOS Rome and PSP scores after aripiprazole augmentation in 16 persons with treatment-resistant schizophrenia who were already treated with clozapine. The results demonstrated a statistically significant improvement in metabolic indices, psychopathology and functional outcome measures from baseline to endpoint (6. weeks) after augmentation with aripiprazole. Statistically significant correlations were observed between psychopathological and behavioural measures at baseline and at endpoint. Linear regression analysis defined a tripartite model, in which item HoNOS Rome 11, measuring autonomy in everyday life, explained nearly half of functional outcome PSP score predictive variance, together with BPRS total psychopathology score and HoNOS Rome total social functioning score. Adequately conducted randomised double-blind studies should provide further specific data highlighting the role of a clozapine-aripiprazole combination in improving functional outcome of persons with treatment-resistant schizophrenia.",
keywords = "Aripiprazole, Clozapine, Retrospective case series, Schizophrenia",
author = "{De Risio}, Alessandro and Angelo Pancheri and Giovanna Simonetti and Diana Giannarelli and Luciana Stefanutto and Bruno Gentile",
year = "2011",
month = "6",
day = "1",
doi = "10.1016/j.pnpbp.2011.03.011",
language = "English",
volume = "35",
pages = "1112--1116",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Add-on of aripiprazole improves outcome in clozapine-resistant schizophrenia

AU - De Risio, Alessandro

AU - Pancheri, Angelo

AU - Simonetti, Giovanna

AU - Giannarelli, Diana

AU - Stefanutto, Luciana

AU - Gentile, Bruno

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Although clozapine proved effective in treating 30-50% of the cases of resistant schizophrenia, its clinical use is hampered by significant side effects. To overcome this problem, augmentation with other atypical antipsychotics has been attempted, with conflicting results. A clozapine-aripiprazole combination showed interesting properties, due to the favourable complementary pharmacodynamic receptor profile and to the negligible metabolic interactions. In this retrospective case series, we investigated the change in BPRS scores and metabolic features like BMI, fasting glucose, total and LDL cholesterol, triglycerides, functional outcome HoNOS Rome and PSP scores after aripiprazole augmentation in 16 persons with treatment-resistant schizophrenia who were already treated with clozapine. The results demonstrated a statistically significant improvement in metabolic indices, psychopathology and functional outcome measures from baseline to endpoint (6. weeks) after augmentation with aripiprazole. Statistically significant correlations were observed between psychopathological and behavioural measures at baseline and at endpoint. Linear regression analysis defined a tripartite model, in which item HoNOS Rome 11, measuring autonomy in everyday life, explained nearly half of functional outcome PSP score predictive variance, together with BPRS total psychopathology score and HoNOS Rome total social functioning score. Adequately conducted randomised double-blind studies should provide further specific data highlighting the role of a clozapine-aripiprazole combination in improving functional outcome of persons with treatment-resistant schizophrenia.

AB - Although clozapine proved effective in treating 30-50% of the cases of resistant schizophrenia, its clinical use is hampered by significant side effects. To overcome this problem, augmentation with other atypical antipsychotics has been attempted, with conflicting results. A clozapine-aripiprazole combination showed interesting properties, due to the favourable complementary pharmacodynamic receptor profile and to the negligible metabolic interactions. In this retrospective case series, we investigated the change in BPRS scores and metabolic features like BMI, fasting glucose, total and LDL cholesterol, triglycerides, functional outcome HoNOS Rome and PSP scores after aripiprazole augmentation in 16 persons with treatment-resistant schizophrenia who were already treated with clozapine. The results demonstrated a statistically significant improvement in metabolic indices, psychopathology and functional outcome measures from baseline to endpoint (6. weeks) after augmentation with aripiprazole. Statistically significant correlations were observed between psychopathological and behavioural measures at baseline and at endpoint. Linear regression analysis defined a tripartite model, in which item HoNOS Rome 11, measuring autonomy in everyday life, explained nearly half of functional outcome PSP score predictive variance, together with BPRS total psychopathology score and HoNOS Rome total social functioning score. Adequately conducted randomised double-blind studies should provide further specific data highlighting the role of a clozapine-aripiprazole combination in improving functional outcome of persons with treatment-resistant schizophrenia.

KW - Aripiprazole

KW - Clozapine

KW - Retrospective case series

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=79956030050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956030050&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2011.03.011

DO - 10.1016/j.pnpbp.2011.03.011

M3 - Article

VL - 35

SP - 1112

EP - 1116

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 4

ER -